Pathological N1/N2 in Clinical Stage I Bronchogenic Carcinoma. Analysis From a Prospective Multicentre Database

Romero Román, Alejandra; Crowley Carrasco, Silvana; Gil Barturen, Mariana; Royuela, Ana; Obiols, Carme; Call, Sergi; Recuero, José Luis; Royo, Íñigo; Embún, Raúl; Gómez de Antonio, David.
Arch. bronconeumol. (Ed. impr.) ; 59(6): 364-369, jun. 2023. ilus, tab
Artículo en Inglés | IBECS (España) | ID: ibc-221388

Documentos relacionados

  1. Lung Cancer: A Wily Genetic Opponent.
  2. Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.
  3. Can Personalized Neoantigens Raise the T Cell Bar?
  4. USNAP: fast unique dense region detection and its application to lung cancer.
  5. High tumor burden in patients with non-small-cell lung cancer: a Delphi survey among Spanish oncologists.
  6. The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
  7. Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs.
  8. Development and validation of prognostic nomogram for T<sub>1-3</sub>N<sub>0</sub>M<sub>0</sub> non-small cell lung cancer after curative resection.
  9. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
  10. Medical management of older patients with lung cancer.